GlassScriptPhysician profile
Teresa D Loera
NPI 1336614858
$14,479.50
in general payments reported to CMS, 2019-2025
26 companies · $5,649 in 2025
The $5,649 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,107 · 2022: $4,111 · 2023: $2,444 · 2024: $1,168 · 2025: $5,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,511 · Consulting Fee: $2,310 · Travel and Lodging: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,510.80 |
| Consulting Fee | $2,310.00 |
| Travel and Lodging | $1,440.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,033.75 | 2021-2025 | Yeztugo, Descovy, Biktarvy |
| Viiv Healthcare Company | $1,705.44 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Roche Diagnostics Corporation | $1,500.00 | 2022 | |
| Abbvie INC. | $659.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $529.43 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $429.95 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $372.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $352.42 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Abbott Laboratories | $321.70 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $307.33 | 2022-2024 | Spravato |
| Janssen Biotech, INC. | $223.76 | 2021-2023 | Symtuza |
| Janssen Products, LP | $216.90 | 2022 | |
| Genzyme Corporation | $201.21 | 2022-2023 | |
| Medtronic, INC. | $176.05 | 2023-2024 | Minimed 780g, Minimed 770g |
| Alkermes, INC. | $137.16 | 2023 | Vivitrol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $97.83 | 2023-2025 | Mytesi |
| Vivus LLC | $30.50 | 2024 | Qsymia |
| Indivior INC. | $29.94 | 2024 | Sublocade |
| Theratechnologies INC. | $28.88 | 2023 | Trogarzo, Egrifta |
| Currax Pharmaceuticals LLC | $28.78 | 2024 | Contrave |
| Oxford Immunotec USA INC | $19.54 | 2022 | |
| Lucid Diagnostics INC. | $16.24 | 2022 | |
| Almatica Pharma LLC | $15.65 | 2024 | Loreev Xr |
| Pfizer INC. | $15.36 | 2023 | |
| Esperion Therapeutics, INC. | $15.15 | 2025 | Nexletol |
| Ascensia Diabetes Care US INC. | $14.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Loera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.